B
1.15
0.00 (0.00%)
| Previous Close | 1.15 |
| Open | 1.15 |
| Volume | 828 |
| 52 Weeks Range |
| Profit Margin | -119.41% |
| Operating Margin (TTM) | -87.08% |
| Quarterly Revenue Growth (YOY) | 12,047.40% |
| Total Debt/Equity (MRQ) | 40.20% |
| Current Ratio (MRQ) | 1.15 |
| Operating Cash Flow (TTM) | -7.03 M |
| Levered Free Cash Flow (TTM) | -4.29 M |
| Return on Assets (TTM) | -69.78% |
| Return on Equity (TTM) | -151.52% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | bioAffinity Technologies, Inc. | - | - |
Stockmoo Score
0.7
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | NA |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.67 |
|
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |